![Long-awaited trial of checkpoint inhibitor in breast cancer produces 2-month PFS gain; no final OS advantage seen—yet](https://cdn.cancerletter.com/media/2018/10/breast-cancer-web.jpg)
![Long-awaited trial of checkpoint inhibitor in breast cancer produces 2-month PFS gain; no final OS advantage seen—yet](https://cdn.cancerletter.com/media/2018/10/breast-cancer-web.jpg)
Cover Story
By Matthew Bin Han Ong
Tecentriq, Genentech's PD-L1 checkpoint inhibitor, is the first immunotherapy agent to report positive outcomes in breast cancer in a phase III trial—providing proof of principle that these drugs are active in treatment of triple-negative breast cancer.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- How a Georgetown med school student found her calling in surgery, law, and health equity
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor
- Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays
- As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.” - Huiping Liu discusses mentorship, translational research on the UChicago Cancer Luminaries podcast